Search the Newsreel

AbbVie (ABBV) Is Down 5.3% After Raising 2026 Revenue Outlook and Issuing New Debt - What's Changed

In late July and early August 2026, AbbVie reported stronger second‑quarter results, raised full‑year revenue guidance to about US$67.6 billion, advanced RINVOQ and BOTOX regulatory milestones, and completed a multi‑billion‑dollar mix of new fixed‑ and floating‑rate bond issuances. Together, these moves highlight how AbbVie …

How Abbott Laboratories (ABT) Affects Rotational Strategy Timing

This article analyzes Abbott Laboratories (ABT) through the lens of rotational strategy timing, utilizing AI models to generate trading strategies. It highlights mixed sentiment, no clear price positioning signal, and compelling upside potential due to the absence of resistance levels above the current price. …

Cabbeen Fashion Declares HK$0.014 Mid-Year Dividend as 2026 Interim Results Signal Steady Discipline

Cabbeen Fashion Limited Reports Earnings Results for the Half Year Ended June 30, 2026

51,393 Shares in Abbott Laboratories $ABT Purchased by St. Louis Financial Planners Asset Management LLC

St. Louis Financial Planners Asset Management LLC recently acquired 51,393 shares of Abbott Laboratories (NYSE:ABT) worth approximately $4.9 million, making it their 10th-largest holding. Institutional investors now own 75.18% of the company, which holds a "Moderate Buy" consensus rating from analysts despite some recent …

What Makes Abbott Laboratories (ABT) a Compelling Investment Opportunity with Reliable Growth

Matrix Asset Advisors, an asset management company, released its Q2 2026 investor letter. A copy of the letter can be downloaded here. The stock market rebounded strongly in the second quarter, with the S&P 500 gaining 15.2% in the quarter and 10.2% year-to-date. Investors …

Abbott (ABT) Stock Trades At A Cash Flow Discount But An Earnings Premium

Abbott Laboratories' stock has dropped 16.4% over the past year, but a Discounted Cash Flow (DCF) analysis suggests a 28.1% upside compared to its current share price, indicating it's undervalued based on future cash flow potential. However, its P/E ratio of 34.6x is higher …

Projeções de Resultados: AbbVie Inc (ABBV) — LPA e Crescimento de Receita

ABB India Consolidated June 2026 Net Sales at Rs 3,558.87 crore, up 7.04% Y-o-Y

Cabbeen Fashion Publishes Unaudited Interim Results for First Half of 2026

Cabbeen Fashion Declares Interim Cash Dividend for First Half of 2026

ABBV6474383 Bond Price and Chart — FINRA:ABBV6474383

This article provides details about the ABBV6474383 bond issued by AbbVie Inc. It lists key terms such as the coupon rate (5.45%), maturity date (September 15, 2038), and outstanding amount. The article also includes company information for AbbVie, Inc., describing it as a research-based …

Regenxbio Inc (RGNX) (Q2 2026) Earnings Call Highlights: Cash Runway Extended into Q4 2027 on ...

This article first appeared on GuruFocus. Cash Position: Ended Q2 2026 with cash, equivalents, and marketable securities of $106 million. Pro Forma Cash: More than $310 million after receiving a $100 million milestone payment from AbbVie and approximately $108 million in net proceeds from …

Knaus Tabbert: Solides H1 bestätigt Erholung auf Kurs; reduzierte Margenprognose spiegelt Gegenwind im H2 wider

AbbVie Inc. (ABBV) Stock forecasts

Argus Research has raised its target price for AbbVie Inc. (ABBV) to $270, noting the company's status as a research-based biopharmaceutical firm spun off from Abbott Laboratories. AbbVie is a component of the S&P 500, with its shares currently trading at $244.93. The report …

Abbott Stock: Is Wall Street Bullish or Bearish?

Abbott Laboratories HQ photo- by Sundry Photography via iStock Lake County, Illinois-based Abbott Laboratories (ABT) discovers, develops, manufactures, and sells health care products worldwide. The company has a market cap of $182.9 billion and operates through Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and …

Knaus Tabbert schreibt wieder schwarze Zahlen - Markt bleibt schwierig

REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights

RGX-202 BLA submission for Duchenne muscular dystrophy on track for Q3 2026 initiation, with potential accelerated approval in 2H 2027 Long-term surabgene lomparvovec (sura-vec, ABBV-RGX-314) data highlight durable safety and efficacy profile ahead of key catalyst Topline data from pivotal subretinal wet AMD studies, …

Knaus Tabbert AG legt Ergebniszahlen für das Halbjahr zum 30. Juni 2026 vor

Knaus Tabbert AG aktualisiert Ergebnisprognose für das Jahr 2026

Earnings Call Transkript: Knaus Tabbert steigert Gewinn im H1 2026 bei sinkendem Umsatz

AbbVie Inc. $ABBV Position Raised by GAMMA Investing LLC

GAMMA Investing LLC increased its holdings in AbbVie Inc. (ABBV) by 8.2% in the second quarter, bringing its total to 68,002 shares valued at $17.1 million. This increase reflects broader institutional confidence, with hedge funds and institutions collectively owning 70.23% of ABBV stock. The …

AbbVie Inc. Stock 12‑Month Price Target Raised to $275.44, Implies 13% Upside

AbbVie Inc.'s stock 12-month average price target has been increased to $275.44 by 25 analysts, up from $274.04. This new target suggests a potential 13% upside based on the Aug. 4 closing price. The consensus rating from 32 analysts remains "Buy," with 24 Buy …

AbbVie Plans to raise $8 billion to finance deal with Apogee Therapeutics

AbbVie Inc. plans to raise $8 billion through investment-grade bonds to fund its $10.9 billion acquisition of Apogee Therapeutics Inc. This strategic move aims to expand AbbVie's portfolio of anti-inflammatory drugs, particularly with Apogee's zumilokibart, a potential competitor to Sanofi's Dupixent. The acquisition reflects …

What AbbVie’s Q2 Earnings Reveal About the Cost of the Apogee Deal

AbbVie's Q2 2026 earnings beat Street estimates across the board, with revenue reaching $16.99 billion and adjusted EPS at $3.65. However, the positive performance was partially offset by a $0.14 dilution from the pending Apogee Therapeutics acquisition, which reduced the full-year guidance upgrade. Despite …

Is AbbVie’s (ABBV) BOTOX Masseter Bet Quietly Rewriting Its Post-Humira Growth Story?

Prediction: AbbVie Will End The Year at This Price

24/7 Wall St. predicts AbbVie (ABBV) will end the year with a "buy" rating and a price target of $297.71, representing a 20.92% upside from its current price. This optimistic outlook is driven by the strong performance of drugs like Skyrizi and Rinvoq, which …

Is It Worth Investing in AbbVie (ABBV) Based on Wall Street's Bullish Views?

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter? Let's …

Baron Capital Exits Apogee Therapeutics (APGE) Following AbbVie Buyout

Baron Capital, an investment management company, released its Q2 2026 investor letter for the "Baron Health Care Fund". A copy of the letter is available to download here. The Fund gained 11.99% during the quarter, compared with the 10.48% gain for the Russell 3000 …

Central Pacific Bank Trust Division Sells 4,628 Shares of AbbVie Inc. $ABBV

Central Pacific Bank Trust Division significantly reduced its stake in AbbVie Inc. by 44.5% in the second quarter, selling 4,628 shares and retaining 5,766 shares valued at $1.45 million. Despite this sale, AbbVie reported strong second-quarter results with revenue up 10.2% and adjusted EPS …

Canandaigua National Bank & Trust Co. Acquires New Stake in AbbVie Inc. $ABBV

Canandaigua National Bank & Trust Co. has acquired a new stake in AbbVie Inc., purchasing 27,540 shares valued at approximately $6.93 million. This comes as AbbVie reported strong second-quarter results, exceeding analyst expectations with revenue up 10.2% year-over-year and solid EPS. The company also …

Top 2 ASX Communications Stocks for August ’26: Aussie Broadband and Macquarie Technology Enter a High-Stakes Growth Contest

AbbVie (ABBV) Wins FDA Review For BOTOX Cosmetic In Jawline Treatment Push

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Allergan Aesthetics, an AbbVie company, reported that the FDA has accepted for review a supplemental Biologics License Application for BOTOX Cosmetic to treat …

AbbVie Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

This article analyzes AbbVie Inc.'s recent earnings beat and the subsequent adjustments made by financial analysts to their future predictions. It will likely cover the company's financial performance, the reasons behind the beat, and how these updated analyst ratings might affect investor sentiment and …

AbbVie Launches $10 Billion Bond Sale to Fund Apogee Acquisition

AbbVie Inc. has initiated a $10 billion bond sale to finance its acquisition of Apogee Therapeutics, as reported by Bloomberg and MT Newswires. This move comes alongside several other recent news items for AbbVie, including positive recommendations for Ubrelvy reimbursement in Canada and FDA …

Abbott vs Danaher: Which Healthcare Stock Looks Better Positioned Following Earnings?

This article compares Abbott Laboratories (ABT) and Danaher Corporation (DHR) following their recent Q2 2026 earnings reports. Abbott showcased strong performance driven by its diagnostics and medical devices segments, leading to an increased annual profit forecast and positive analyst sentiment. Danaher, while showing core …